CATALYST PHARMACEUTICALS INC. - COMMON STOCK

Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

26 10 2023 15:19:11 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023

23 10 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

19 10 2023 08:03:00 提供 Nasdaq GlobeNewswire

Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

16 10 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

13 10 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

18 9 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

16 8 2023 10:56:47 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

14 8 2023 08:05:10 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

09 8 2023 16:17:05 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

19 7 2023 06:00:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

20 6 2023 06:00:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

01 6 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

30 5 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

10 5 2023 16:28:05 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

09 5 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

01 5 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

24 4 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

20 4 2023 08:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

15 3 2023 16:11:45 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

08 3 2023 11:20:58 提供 Nasdaq GlobeNewswire